KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Diluted Average): 2012-2024

Historic Shares Outstanding (Diluted Average) for Xenon Pharmaceuticals (XENE) over the last 10 years, with Dec 2024 value amounting to $77.9 million.

  • Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.70% to $79.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.2 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $77.9 million for FY2024, which is 16.45% up from last year.
  • Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $77.9 million in FY2024, which was up 16.45% from $66.9 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $77.9 million for FY2024, and its period low was $34.5 million during FY2020.
  • For the 3-year period, Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $68.4 million, with its median value being $66.9 million (2023).
  • Data for Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 38.77% (in 2022) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $34.5 million in 2020, then climbed by 26.30% to $43.6 million in 2021, then soared by 38.77% to $60.5 million in 2022, then grew by 10.48% to $66.9 million in 2023, then climbed by 16.45% to $77.9 million in 2024.